WallStreetZenWallStreetZen

NASDAQ: AARD
Aardvark Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AARD

Based on 7 analysts offering 12 month price targets for Aardvark Therapeutics Inc

Min Forecast
$3.00-54.55%
Avg Forecast
$8.29+25.55%
Max Forecast
$21.00+218.18%

Should I buy or sell AARD stock?

Based on 7 analysts offering ratings for Aardvark Therapeutics Inc.

Buy
Strong Buy
2 analysts 28.57%
Buy
1 analysts 14.29%
Hold
3 analysts 42.86%
Sell
0 analysts 0%
Strong Sell
1 analysts 14.29%
Although AARD's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates AARD as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their AARD stock forecasts and price targets.

AARD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-20
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-03-24
lockedlocked$00.00+00.00%2026-03-02
Stifel Nicolaus
Top 41%
60
HoldDowngrades$6.00-9.09%2026-03-02
RBC Capital
Top 10%
91
HoldDowngrades$6.00-9.09%2026-03-02

1 of 1

Forecast return on equity

Is AARD forecast to generate an efficient return?

Company
-39.31%
Industry
87.23%
Market
180.82%
AARD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AARD forecast to generate an efficient return on assets?

Company
-34.68%
Industry
26.37%
AARD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AARD earnings per share forecast

What is AARD's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.68
Avg 2 year Forecast
-$3.22
Avg 3 year Forecast
-$2.90

AARD revenue forecast

What is AARD's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$6.8M

AARD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AARD$6.60$8.29+25.55%Buy
CRBU$1.46$12.33+744.73%Strong Buy
HUMA$0.65$5.25+703.98%Strong Buy
INDP$1.29N/AN/A
ENTX$2.99$9.00+201.00%Buy
View Top Biotech Stocks

Aardvark Therapeutics Stock Forecast FAQ

Is Aardvark Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: AARD) stock is to Buy AARD stock.

Out of 7 analysts, 2 (28.57%) are recommending AARD as a Strong Buy, 1 (14.29%) are recommending AARD as a Buy, 3 (42.86%) are recommending AARD as a Hold, 0 (0%) are recommending AARD as a Sell, and 1 (14.29%) are recommending AARD as a Strong Sell.

If you're new to stock investing, here's how to buy Aardvark Therapeutics stock.

What is AARD's earnings growth forecast for 2026-2028?

(NASDAQ: AARD) Aardvark Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.

Aardvark Therapeutics's earnings in 2026 is -$69,869,000.On average, 14 Wall Street analysts forecast AARD's earnings for 2026 to be -$80,221,029, with the lowest AARD earnings forecast at -$94,072,252, and the highest AARD earnings forecast at -$46,501,625. On average, 14 Wall Street analysts forecast AARD's earnings for 2027 to be -$70,207,309, with the lowest AARD earnings forecast at -$128,066,543, and the highest AARD earnings forecast at -$33,902,662.

In 2028, AARD is forecast to generate -$63,308,968 in earnings, with the lowest earnings forecast at -$125,714,737 and the highest earnings forecast at -$22,219,988.

What is AARD's revenue growth forecast for 2026-2028?

(NASDAQ: AARD) Aardvark Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.

Aardvark Therapeutics's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast AARD's revenue for 2026 to be $0, with the lowest AARD revenue forecast at $0, and the highest AARD revenue forecast at $0. On average, 13 Wall Street analysts forecast AARD's revenue for 2027 to be $0, with the lowest AARD revenue forecast at $0, and the highest AARD revenue forecast at $0.

In 2028, AARD is forecast to generate $148,373,234 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $687,216,128.

What is AARD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AARD) forecast ROA is -34.68%, which is lower than the forecast US Biotechnology industry average of 26.37%.

What is AARD's Price Target?

According to 7 Wall Street analysts that have issued a 1 year AARD price target, the average AARD price target is $8.29, with the highest AARD stock price forecast at $21.00 and the lowest AARD stock price forecast at $3.00.

On average, Wall Street analysts predict that Aardvark Therapeutics's share price could reach $8.29 by Jul 20, 2027. The average Aardvark Therapeutics stock price prediction forecasts a potential upside of 25.55% from the current AARD share price of $6.60.

What is AARD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AARD) Aardvark Therapeutics's current Earnings Per Share (EPS) is -$3.21. On average, analysts forecast that AARD's EPS will be -$3.68 for 2026, with the lowest EPS forecast at -$4.31, and the highest EPS forecast at -$2.13. On average, analysts forecast that AARD's EPS will be -$3.22 for 2027, with the lowest EPS forecast at -$5.87, and the highest EPS forecast at -$1.55. In 2028, AARD's EPS is forecast to hit -$2.90 (min: -$5.76, max: -$1.02).

What is AARD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AARD) forecast ROE is -39.31%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.